News | April 20, 2026
Lupin subsidiary settles US antitrust case with Humana for $30 Million
The litigation involved multiple civil lawsuits alleging anti-competitive practices and violations of federal
The litigation involved multiple civil lawsuits alleging anti-competitive practices and violations of federal
Analysts expect modest revenue growth but pressure on profitability in the March quarter
The move aims to accelerate the development, commercialization, and global rollout of advanced AI-powered mammography tools
New purpose-built AI model targets faster R&D cycles and deeper scientific insights across life sciences
ICMR-led consultation calls for stricter HFSS regulations, nutrition literacy, and healthier food environments
The goal is to better support drug developers as programs move from laboratory research into clinical trials
At the centre of this shift is Eli Lilly and Company, whose latest investments in China and Japan are helping redefine the next phase of GLP-1 supply strategy
In just the last few days, companies including Lupin, Biocon, Alembic Pharmaceuticals and Aurobindo Pharma have announced approvals for 5 mg and 10 mg tablets, all bioequivalent to Farxiga
AI challenge offers Rs 10 lakh top prize and potential ?50 lakh deployment contract; applications open till April 17
The acquisition adds VYKAT XR (diazoxide choline), the first FDA-approved therapy for hyperphagia in Prader-Willi syndrome (PWS), a rare genetic disorder, to Neurocrine’s portfolio
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
